Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex & ORCID
How has David Planchard's publication output changed over time?
ScholarIQpublication output · 2015–2021
Output declined50% over the shown period — from 2 works in 2015 to 1 in 2021.
2
1
3
4
1
1
201520162017201820192021
What are the most-cited papers on David Planchard?
ScholarIQmost cited works
Osimertinib in Untreated <i>EGFR</i> -Mutated Advanced Non–Small-Cell Lung Cancer
Jean‐Charles Soria, Yuichiro Ohe, Johan Vansteenkiste, Thanyanan Reungwetwattana, Busyamas Chewaskulyong, Ki Hyeong Lee, Arunee Dechaphunkul, Fumio Imamura, Naoyuki Nogami, Takayasu Kurata, Isamu Okamoto, Caicun Zhou, Byoung Chul Cho, Ying Cheng, Eun Kyung Cho, Pei Jye Voon, David Planchard, Wu‐Chou Su, Jhanelle E. Gray, Siow Ming Lee, Rachel Hodge, Marcelo Marotti, Yuri Rukazenkov, Suresh S. Ramalingam
New England Journal of Medicine. 20175,376 CitationsOPEN ACCESS
Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer
Scott Antonia, Augusto Villegas, Davey B. Daniel, David Vicente, Shuji Murakami, Rina Hui, Takashi Yokoi, Alberto Chiappori, Ki Hyeong Lee, Maike de Wit, Byoung Chul Cho, Maryam Bourhaba, Xavier Quantin, Takaaki Tokito, Tarek Mekhail, David Planchard, Young‐Chul Kim, Christos S. Karapetis, Sandrine Hiret, Gyula Ostoros, Kaoru Kubota, Jhanelle E. Gray, Luis Paz‐Ares, Javier de Castro, Catherine Wadsworth, Giovanni Melillo, Haiyi Jiang, Yifan Huang, Phillip A. Dennis, Mustafa Özgüroğlu
New England Journal of Medicine. 20174,592 CitationsOPEN ACCESS
Overall Survival with Osimertinib in Untreated, <i>EGFR</i> -Mutated Advanced NSCLC
Suresh S. Ramalingam, Johan Vansteenkiste, David Planchard, Byoung Chul Cho, Jhanelle E. Gray, Yuichiro Ohe, Caicun Zhou, Thanyanan Reungwetwattana, Ying Cheng, Busyamas Chewaskulyong, Riyaz Shah, Manuel Cobo, Ki Hyeong Lee, Parneet Cheema, Marcello Tiseo, Thomas John, Meng‐Chih Lin, Fumio Imamura, Takayasu Kurata, Alexander Todd, Rachel Hodge, Matilde Saggese, Yuri Rukazenkov, Jean‐Charles Soria
New England Journal of Medicine. 20192,875 CitationsOPEN ACCESS
Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC
Scott Antonia, Augusto Villegas, Davey B. Daniel, David Vicente, Shuji Murakami, Rina Hui, Takayasu Kurata, Alberto Chiappori, Ki Hyeong Lee, Maike de Wit, Byoung Chul Cho, Maryam Bourhaba, Xavier Quantin, Takaaki Tokito, Tarek Mekhail, David Planchard, Young‐Chul Kim, Christos S. Karapetis, Sandrine Hiret, Gyula Ostoros, Kaoru Kubota, Jhanelle E. Gray, Luis Paz‐Ares, Javier de Castro, Corinne Faivre‐Finn, Martin Reck, Johan Vansteenkiste, David R. Spigel, Catherine Wadsworth, Giovanni Melillo, Maria Taboada, Phillip A. Dennis, Mustafa Özgüroğlu
New England Journal of Medicine. 20182,828 CitationsOPEN ACCESS
Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
David Planchard, Sanjay Popat, Keith M. Kerr, Silvia Novello, Egbert F. Smit, Corinne Faivre‐Finn, Tony Mok, Martin Reck, Paul E. Van Schil, Matthew D. Hellmann, Solange Peters
Annals of Oncology. 20182,311 CitationsOPEN ACCESS
Related on ScholarIQ
Inserm
Institution
Osimertinib in Untreated <i>EGFR</i> -Mutated Advanced Non–Small-Cell Lung Cancer
Paper
Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer
Paper
Overall Survival with Osimertinib in Untreated, <i>EGFR</i> -Mutated Advanced NSCLC
Paper
Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC
Paper
Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Paper